Editorial
Sildenafil for pulmonary hypertension complicating bronchopulmonary dysplasia Expert Review of Clinical Pharmacology Downloaded from informahealthcare.com by Selcuk Universitesi on 02/11/15 For personal use only.
Expert Rev. Clin. Pharmacol. 7(4), 393–395 (2014)
Varsha Bhatt-Mehta College of Pharmacy, University of Michigan Health System, Ann Arbor, MI 48109-5254, USA and Department of Pediatrics, University of Michigan Health System, Ann Arbor, MI 48109-5254, USA
Steven M Donn Author for correspondence: Department of Pediatrics, University of Michigan Health System, Ann Arbor, MI 48109-5254, USA and Division of Neonatal-Perinatal Medicine, C.S. Mott Children’s Hospital, 1540 E. Hospital Drive, University of Michigan Health System, Ann Arbor, MI 48109-5254, USA Tel.: +73 4763 4109 Fax: +73 4763 7728
[email protected] Sildenafil, a phospohodiesterase-5 inhibitor, is widely used to treat pulmonary hypertension in infants with bronchopulmonary dysplasia despite a lack of evidence to support either safety or efficacy and US FDA advice against its use.
Bronchopulmonary dysplasia (BPD) is a common complication of preterm infants treated with mechanical ventilation. The incidence is inversely proportional to gestational age, affecting 30–40% of infants